Analytical Data
-
Gene name
hld
- Application
-
Alternative Names
(Delta-lysin)(Delta-toxin)
-
Species
Staphylococcus aureus
-
Source
E. coli
-
Tag
N- His-KSI
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P0A0M1
-
Expression Region
1-26aa
-
Molecular Weight
18.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HLD, or high-density lipoprotein, is a vital component of plasma lipid transport and metabolism, playing a significant role in cardiovascular health. The research surrounding HLD recombinant proteins has surged due to their potential therapeutic applications, particularly in treating diseases such as atherosclerosis and other lipid-related disorders. Understanding the structure and function of HLD proteins is crucial for developing effective treatments, as these proteins are involved in cholesterol transport, reverse cholesterol transport, and modulating inflammation. Recent advances in biotechnology have enabled the successful recombinant expression of HLD proteins, allowing researchers to study their functional properties in detail. The manipulation of these proteins can lead to insights into their role in lipid metabolism and cardiovascular disease, providing a foundation for novel therapeutic strategies. Furthermore, the engineering of HLD proteins may improve their efficacy as drug candidates, with applications potentially extending to regenerative medicine and metabolic syndrome management. As the prevalence of cardiovascular diseases continues to rise globally, the pursuit of innovative and effective biological therapies involving HLD recombinant proteins is more critical than ever, highlighting the need for continued research in this promising field.
